Scientific reports, 2024-03, Vol.14 (1), p.7534-7534
2024
Details
- Autor(en) / Beteiligte
- Titel
- No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients
- Ist Teil von
- Scientific reports, 2024-03, Vol.14 (1), p.7534-7534
- Ort / Verlag
- England: Nature Publishing Group
- Erscheinungsjahr
- 2024
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Untreated HCV mono and HCV/HIV coinfected women have lower degrees of liver fibrosis (LF) compared to men. Direct acting antiviral (DAA) therapy attains viral eradication in > 90% of patients with progressive LF decline in parallel. Gender-related differences in LF regression in the long term assessed by non-invasive liver fibrosis markers (NILFM) in HCV mono and HCV/HIV coinfected after DAA treatment have not been explored so far. 374 HCV-infected adult patients, 214 of them HCV/HIV coinfected, were followed-up for 24 months after starting DAA therapy. LF was assessed by NILFM: transient elastometry (TE) and several biochemical indexes (APRI, Forns, FIB-4). Men had significantly more advanced LF at baseline than women assessed by NILFM. No LF differences at baseline in age, HIV coinfection course (CD4, HIV viral load), and HCV features (HCV viral load, genotype) were detected. No significant gender differences in LF decline after comparing 24-month and baseline LF values were observed. LF changes after DAA therapy were similar in HCV mono and HCV/HIV coinfected patients and in both sexes. Gender did not influence the course of LF decline after DAA assessed by NILFM: TE (P = 0.8), APRI (P = 0.9), Forns (P = 0.4) and FIB-4 (P = 0.7) by multivariate analysis. No gender differences in the 24 month LF decline after DAA with independence of having HCV mono or HCV/HIV coinfection were found.
- Sprache
- Englisch
- Identifikatoren
- eISSN: 2045-2322DOI: 10.1038/s41598-024-57845-xTitel-ID: cdi_doaj_primary_oai_doaj_org_article_f92bfb26578149c68d9dad4ae2faf312
- Format
- –
- Schlagworte
- Adult, Antiviral Agents - therapeutic use, CD4 antigen, Coinfection - drug therapy, Direct-acting antivirals, Female, Fibrosis, Gender, Gender differences, Genotypes, Hepacivirus - genetics, Hepatitis C, Hepatitis C, Chronic - complications, Hepatitis C, Chronic - drug therapy, HIV, HIV Infections - complications, HIV Infections - drug therapy, Human immunodeficiency virus, Humans, Liver, Liver cirrhosis, Liver Cirrhosis - complications, Liver Cirrhosis - drug therapy, Liver fibrosis, Male, Multivariate analysis, Sex differences, Sex Factors, Transient elastometry